Stem cells and neurological disease

R A Barker, M Jain, R J E Armstrong, M A Caldwell

The therapeutic implications and application of stem cells for the nervous system

There has recently been a great deal of interest in stem cells and the nervous system, in terms of their potential for deciphering developmental issues as well as their therapeutic potential. In this editorial we will critically appraise the different types of stem cells, their therapeutic implications, and the applications to which they have been put, with the hope that the hype that surrounds these cells can be distinguished from the scientific reality.

WHAT ARE STEM CELLS?

Stem cells were originally defined in the haematological system, but more recently have been found in a multitude of other sites, including the brain. These cells all share the same properties of self-renewal and multipotentiality and various different types and therapeutic strategies have been defined with respect to the nervous system (Table 1, fig 1).

The reasons for these cells receiving such attention for the treatment of neurological disorders relates to their:

- (a) capacity to proliferate in culture with the prospect that large numbers of cells can be derived from a limited source;
- (b) potential to be harvested from the patients themselves;
- (c) ability to migrate and disseminate following implantation within the adult CNS;
- (d) possible tropism for areas of pathology;
- (e) ease of manipulation using viral and non-viral gene transfer methods;
- (f) ability to better integrate into normal brain cytoarchitecture with the potential for physiologically regulated release of substances.

We will briefly discuss the different types of stem cells and how they have been applied to neurological disease, especially Parkinson’s disease, given the accepted view that this is the disease most amenable to cell replacement therapy.

EMBRYONIC STEM CELLS

Embryonic stem cells are derived from the inner cell mass of the embryonic blastula and are pluripotent with great proliferative potential, although with this comes the risk of teratomas. Much of the work to date has concentrated on mouse derived embryonic stem cells, which can be made to differentiate into neurons, including dopaminergic neurons. These latter cells have been shown to survive and ameliorate behavioural deficits in an animal model of Parkinson’s disease, although in this study 20% of rats still developed teratomas at the transplant site. In contrast, Kim et al., using a different approach that relies on transfection with Nurrl (a transcription factor involved in the differentiation of dopaminergic cells), have demonstrated functional efficacy without tumour formation.

Human embryonic stem cells have now been isolated and grown in culture with enrichment for neuronal lineages, possible through exposure to a combination of growth factors and mitogens. These cells, when placed in the developing rat brain, can migrate widely and differentiate in a site-specific fashion without the formation of teratomas. However, the safety of these cells needs further investigation before they can be considered for clinical use. Furthermore, the sensitive nature of this technology and the ethical issues surrounding it make it a very controversial source of tissue for cell replacement therapy and in this respect the issue of therapeutic cloning is a major concern.

ADULT NEURAL PRECURSOR CELLS

One of the long held dogmas is that neurogenesis in the adult mammalian central nervous system (CNS) does not occur, although there is now ample evidence to suggest that this is not the case. New neurons are derived in adulthood from a population of adult neural precursor cells (NPCs), which are primarily found in the subependymal layer of the ventricular zone and the dentate gyrus of the hippocampus, although they are also probably found in other sites. However, the behaviour of the NPCs found in all these sites is different, and may relate as much to the environment in which

Table 1 Essential properties of stem cells for use in clinical transplantation

<table>
<thead>
<tr>
<th>Disease</th>
<th>Principle function required of stem cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell replacement</td>
<td>Nigrostriatal dopamine neurons</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>GABAergic striatal projection neurons</td>
</tr>
<tr>
<td>Huntington’s disease</td>
<td>Diffuse neuronal replacement, including basal forebrain cholinergic</td>
</tr>
<tr>
<td>Alzheimer’s and other dementias</td>
<td>Nigrostriatal and striatal output neurons</td>
</tr>
<tr>
<td>Multiple system atrophy (MSA)</td>
<td>Hippocampal neurons especially those of CA1</td>
</tr>
<tr>
<td>Focal ischaemic damage</td>
<td>Broad phenotypes required, dependent on site</td>
</tr>
<tr>
<td>Traumatic brain injury</td>
<td>Broad phenotypes required; dependent on site</td>
</tr>
<tr>
<td>Spinal injury</td>
<td>Projection neurons [glutamate]; remyelination</td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis</td>
<td>Replacement of alpha motorneurons</td>
</tr>
<tr>
<td>Multiple sclerosis and other demyelinating conditions</td>
<td>Remyelination through oligodendrocytes</td>
</tr>
<tr>
<td>Drug delivery</td>
<td>Local GABA</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>Analgesic compounds such as met-enkephalin and endorphins</td>
</tr>
<tr>
<td>Chronic pain</td>
<td>Metabolic enzymes</td>
</tr>
<tr>
<td>Genetic defects, e.g. Mucopolysaccaroidis VII</td>
<td>β-glucuronidase</td>
</tr>
<tr>
<td>Tay-Sachs disease</td>
<td>β-hexosaminidase A</td>
</tr>
<tr>
<td>“growth factor responsive conditions”</td>
<td>Anti-mitotic drug; modified viruses</td>
</tr>
<tr>
<td></td>
<td>Support of diverse neuronal populations</td>
</tr>
</tbody>
</table>
neurogenesis in the adult human CNS. There is now evidence of this process in the adult human CNS, with recent suggestions that newborn neurons in the adult CNS are capable of migration and survival and in vitro can be made to express markers of astrocytes, oligoden-droglia, and neurons.

Indeed they have even been associated with some functional benefit in a rodent model of Parkinson’s disease when transplanted into the dopamine-synthesising nigrostriatal pathway in PD. However, the robustness and efficiency of this system to produce neural cells is still poor, as is its widespread applicability to other types of non-neural stem cells. There is some evidence from cDNA microarray analysis that different stem cells may in fact have similar phenotypic potential irrespective of origin, and, therefore, it is theoretically possible that stem cells derived from non-neural systems may be used for neural cell therapy through a transdifferentiation process. However, there have been recent concerns that such a process may be a result of cell fusion—namely adult somatic cells can appear to gain differentiation potential by fusion with less differentiated cells.

**BONE MARROW AND NON-NEURAL STEM CELLS**

An alternative source of autologous cells for grafting in patients with neurological disease are those derived from non-neural sources including the bone marrow, which contains a range of stem cells. This includes the haematopoietic stem cell, which when transplanted into irradiated recipients can migrate into the brain and differentiate into microglia, astrocytes, and possibly neurons. In addition, there are mesenchymal stem cells or bone marrow stromal cells, which when engrafted into the adult brain are capable of migration and survival and in vitro can be made to express markers of astrocytes, oligoden-droglia, and neurons.

Although much of this work has been done in rodents there is now evidence of neurogenesis in the adult human hippocampus, with cells being grown from the adult human CNS. Thus, the potential for autologous grafts is possible, assuming that the NPCs are not themselves involved in the disease process, and has indeed already been attempted in one patient with Parkinson’s disease.

**EMBRYONIC NEURAL STEM CELLS (NSCs)**

Most of the work on stem cells and the CNS refers to NSCs that are derived from the neuroepithelium of the developing embryo. These cells respond in vitro to mitogens such as epidermal growth factor (EGF) and fibroblast growth factor (FGF2), and it is possible to expand cells from any region of the brain. As development progresses to adulthood there is considerable debate over the origin of NSCs, with recent suggestions that these cells may also originate from glia. Radial glia have classically been considered to be “scaffolding” cells along which cortical neuroblasts migrate to reach their final destination, after which they differentiate into astrocytes. However, recent in vitro and in situ studies suggest that the radial glial cells may be responsible for the production of newborn neurons, as well as their guidance to their final destinations within the cortex.

The exact relationship of this cell type to the NSCs derived from the neuroepithelium is yet to be elucidated, although it is possible that as development time increases, stem cells have either neuroepithelial, radial glial, or finally astroglial characteristics, which all share the characteristic of nestin expression.

The isolation of these cells is complicated because their culturing inevitably leads to a mixed population of progenitor and stem cells, which can better be described as expanded neural precursors (ENPs). In addition, the proliferation of ENPs in culture is not indefinite because there appears to be a set number of population doublings—the so-called “Hayflick limit”, equivalent to approximately 50 population doublings after which non-transformed cells enter replicative senescence and stop dividing. This effect seems to be species dependent, and although greater for human than rodent ENPs, obviously has important implications for their clinical application.

Attempts to circumvent this problem with human cells has employed either a modification of the culture technique or the use of transducing vectors encoding an immortalising oncogene. These genetic manipulations may alter the behaviour of these cells even without tumorigenesis, and thus extrapolation of results from such cells to those found in the developing and adult CNS must be carried out with caution.

For ENPs to be of clinical value, they not only need to be propagated long term in culture, but must be able to differentiate appropriately, which is influenced both by intrinsic and external factors, such as the culture conditions. This having been said, neurons differentiating from growth factor responsive ENPs are typically GABAergic in phenotype, irrespective of species or region from which the cells were harvested in the embryo. So for most disorders, especially Parkinson’s disease, it will be necessary to switch or regulate their fate and a number of factors and methods have been suggested for the generation of dopaminergic neurons based on factors known to be important in their normal development (see also embryonic stem cell section; see figure 2).

Exposure of ENPs to sonic hedgehog (Shh) or transcription factors, including nurr1, has been shown to increase

---

The different types of stem cells

---

www.jnnp.com
the yield of dopaminergic neurons obtained from these cells, although not all cell types respond to such stimulation, for example hNT neurons. However, in most cases only small numbers of such neurons emerge from these manipulations, and thus the search continues for a reliable culture method to obtain sufficient numbers of dopaminergic neurons.

TRANSPLANTATION OF NEURAL STEM CELLS FOR THE TREATMENT OF NEUROLOGICAL DISEASE

The behaviour of embryonic NSCs following transplantation varies depending on the source of cell and animal model. In the case of human ENPs and the intact adult brain, it has been shown that they are able to generate neurons in vivo in regions of active neurogenesis such as the SVZ and hippocampus, but not when placed in non-neurogenic areas such as the striatum. The situation may be different in the diseased or damaged CNS (see table 1).

Parkinson’s disease

Early transplant studies using human ENPs showed some survival and dopaminergic differentiation, but the numbers were low. This may relate to the fact that in vitro, NPCs derived from the developing ventral mesencephalon lose the ability to spontaneously differentiate into dopaminergic cells after only a few divisions. Thus, “pre-differentiation” of the ENPs prior to implantation would seem logical and this approach has been adopted with some success by Studer and colleagues.

Huntington’s disease

Transplantation repair in Huntington’s disease provides different challenges for ENPs, in that the transplanted cells must homotypically reconstruct circuitry. To date, studies using NSCs in this disorder are limited but there is some evidence of appropriate neuronal differentiation with human NSCs, although the functional efficacy and connectivity of these cells in repairing the brain has not been demonstrated.

Cerebral ischaemia

Cell replacement therapy for ischaemic injury has experimentally shown some promise. For example, transplantation of the MHP36 line (ReNeuron Holdings) has been reported to ameliorate cognitive deficits in rodent models of ischaemia. However, the applicability of these findings to ENPs in general is uncertain because other similarly derived multipotential cell lines do not show such an ability. hNT neurons derived from a human teratocarcinoma cell line have also been shown to alleviate motor and behavioural deficits in animal models of ischaemia, although it is hard to attribute the functional recovery to circuit reconstruction given the histological findings. Nevertheless, some investigators have deemed this to be sufficient data to move to a clinical trial in patients with basal ganglia stroke and resultant motor deficits. Reassuringly, there has been no evidence for tumorigenesis or other adverse effects in the 12 patients who have been reported in the phase I study, although preliminary functional and imaging data are difficult to interpret because of the lack of an adequate control group. There is, however, at least some evidence of cell survival based on postmortem data 27 months post-transplantation.

Demyelinating diseases

ENPs are also being considered to replace glial cells that have been lost to demyelinating or dysmyelinating disease. Animal models of global hypomyelination (eg the shiverer (Shi) mouse) have been used to examine the ability of transplanted ENPs to myelinate axons. Oligodendrocytes constitute a very small component of the differentiated cells that emerge spontaneously in vitro from both EGF/FGF-2-expanded ENPs and most of the genetically immortalised stem cell lines. However, when such cells are transplanted into the myelin deficient environment, an increase in oligodendroglial differentiation has been reported, which is associated with some myelination and in some cases a degree of functional recovery.

APPLICATIONS OF NSCS AS VECTORS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES

In addition to their potential to directly replace cells lost to disease and thereby reconstruct the CNS, NSCs might also serve a role as efficient and flexible vectors for the sustained, local delivery of neuroactive compounds to the brain—eg neurotrophic factors for neuroprotection, or to replace proteins lost because of single gene defects. In most envisioned scenarios this would involve genetically engineering the NSCs to direct, and regulate, the expression of therapeutic gene products (ex vivo gene therapy).

Treatment of genetic disorders

The aetiology of a number of rare, but devastating, inherited neurological conditions can be fully attributed to the loss of function of a single gene that encodes for a metabolically or developmentally critical enzyme. The ability of stem cells to deliver functional enzymes diffusely in such neurogenetic degenerative conditions has been explored in some prototypical animal models such as that for mucopolysaccharidosis type VII (MPS VII, Morquio).

Neurotrophins and cytokines for neuroprotection

The understanding that the differentiation and survival of neurons in development is dependent on them receiving...
adequate and specific trophic support has meant that a number of cell delivery systems have been examined, including NSCs. Such a delivery strategy is attractive compared to a viral vector based delivery system because the host brain is not genetically manipulated, preventing insertional mutagenesis and preserving the function of neurons in the host. In addition, NSCs can be fully characterised such that the level of production of the growth factor can be standardised, and, finally, extra safety features could be incorporated, such as a “suicide cassette”, which would allow for elimination of cells should it be necessary.14

Chemotherapeutic agents

Obtaining adequate local concentrations of cytotoxic drugs impedes the chemotherapy of primary brain tumours. Based on their previous work indicating that the C17.2 NSC line was highly migratory in the adult brain, Snyder and colleagues retrovirally transduced this cell line to express the anti-mitotic compound cytosine deaminase. These cells were implanted into animals, with experimentally induced gliomas and appeared to migrate preferentially towards the tumours, which decreased in size.15 In a similar vein, the same group has recently reported a method by which the migratory ability of this line can be harnessed as a “Trojan horse” to deliver therapeutic viruses to intracerebral tumours.16 Although such results require confirmation and more characterisation, they suggest that certain ENPs may show a tropism for areas of pathology and may be of use in chemotherapy.

Drug discovery and therapeutics

Finally, stem cells are an attractive option for commercial organisations interested in drug discovery.17

CONCLUSION

Stem cells are emerging as one of the most exciting new areas of neuroscience, not only in terms of revealing insights into normal development, but also as a therapeutic agent for a range of neurological diseases. In both of these aspects, they will impinge on neurological practice by providing insights into mechanisms of disease as well as curative cell therapies. However, the development of such approaches requires patience and any translation from the laboratory to the clinic must be undertaken slowly and based on sound experimental data. A failure to do so will not only undermine those involved in this type of research, but will prematurely dash the hopes of many patients and their neurologists.

ACKNOWLEDGEMENTS

The authors’ own works are supported by the MRC, PDS, Royal Society and Merck Sharp, and Dohme. We apologise to all those whose work has not been cited because of space constraints.

REFERENCES


www.jnnp.com
What is wrong in conversion disorder?

F Ovsiew

A disorder with many names

The article by Stone et al (this issue, p 591–596) addresses the natural history of a disorder with many names, none satisfactory. Functional, hysterical, psychogenic, medically unexplained, dissociative, conversion—all the names for this disorder have their faults. Yet the disorder is common, poses a management problem for doctors, and carries a poor prognosis. What is wrong with these patients?

What is now clearly known not to be wrong is the occult presence of a neurological disorder. Several follow up studies, this one included, show that the rate of erroneous diagnosis is low; neurological disease is not being missed when conversion disorder is diagnosed. Techniques of neurological examination that allow recognition of non-organic manifestations have been described, although patients with organic disease may—because of suggestibility and the “demand characteristics” of the setting—generate non-organic signs if called on to do so by inappropriate examination.

The follow up studies also show that most patients with conversion disorder have persisting, or remitting and relapsing, somatic symptoms. In addition, they have impairment of psychological and social functioning outside the sphere of medically unexplained somatic symptoms. For example, they often have mood disorders, self-injurious behaviour, dissociative symptoms, and interpersonal difficulties.

In summary, conversion disorder appears to be a disorder of affect regulation and symbolisation, in which somatic experiences and complaints serve to represent and convey emotional distress, a purpose to which they are poorly suited. Ideally, the management of these patients centres on the formation of a treatment relationship not to catch the patient out but to allow exploration of areas of the patient’s life outside the presenting symptoms and construction of a plan to reduce distress (including focused treatment of commonly coexisting depressive disorder), and to develop alternative ways of seeking attention and assistance for distress.

J Neurol Neurosurg Psychiatry 2003;74:557

Author’s affiliation

F Ovsiew, Department of Psychiatry MC3077, University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USA; fovsiew@uchicago.edu

REFERENCES


